TG Therapeutics rises as European regulator backs multiple sclerosis drug

TG Therapeutics

31/03/2023 14:17

** Shares of drug developer TG Therapeutics Inc  TGTX.O 
rise ~6% to $15.5 premarket 
    ** Co says the European health regulator's Committee for
Medicinal Products for Human Use recommended approval of its
drug candidate to treat adult patients with relapsing forms of
multiple sclerosis    
    ** The recommendation is based on data from two late-stage
trials showing significant reduction in relapse rate among
patients -TGTX
    ** The drug ublituximab is approved in the U.S. for the same
indication and is sold under the brand name Briumvi -TGTX  
    ** Multiple sclerosis is a neurological disease in which the
immune system attacks the brain cells causing motor disabilities
    ** As of last close, stock rose ~24% this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))